Bli medlem
Bli medlem

Du är här


Eckert & Ziegler BEBIG: Eckert & Ziegler BEBIG announces the launch of SagiNova® and SagiPlan® for HDR brachytherapy

Seneffe, Belgium, April 23rd, 2015.
Eckert&Ziegler BEBIG is proud to announce the global launch of its new
afterloader SagiNova® and the corresponding treatment planning system
SagiPlan® at the 3rd ESTRO Forum in Barcelona, Spain.

SagiNova® is derived from the latin words 'Sagitta' and 'novum' which mean
arrow and new. With SagiNova®, Eckert&Ziegler BEBIG offers the most modern
HDR afterloader with precise, arrow-like targeting. "It is our ambition to
incorporate customer needs into product development. The newest technology
inside fulfills today's global customer demands regarding safety, seamless
workflows, and cost efficiency as well as regulatory demands; it also builds
a platform for further development," says Abel Luzuriaga, Managing Director
of Eckert&Ziegler BEBIG.

SagiNova® incorporates the outstanding features of the MultiSource®
afterloader such as the choice between a cobalt-60 and iridium-192 source,
the integrated In-Vivo Dosimetry System, automatic path length measurement
and digital source position verification. A new hardware and software
platform allows for new features like the highly customizable tool QAssist
that supports users in a straightforward way to adhere to the highest quality
assurance standards with full digital documentation. It offers pre-defined
quality assurance tests which verify whether the system and critical
components are operating correctly. QAssist configurations can be shared with
partnering departments to allow for consistent quality reporting.
The remote support implemented with SagiNova® allows for short response times
and enhanced service support. Additionally, the 40 channel support of
MultiSource® was refined to 50 channel support in SagiNova®.

The new SagiNova® and SagiPlan® graphical user interfaces (GUI) were developed
in cooperation with brachytherapy experts and usability engineers leading to
the development of the next level of smooth and efficient workflow guidance.
Besides the new intuitive and modern GUI, SagiPlan® includes an improved
prostate module regarding image registration and treatment visualization
features. Additionally, a needle placement helper was introduced with
automatic needle labeling and channel template assignment report was added
together with many other features to allow for an improved workflow.

SagiNova® and SagiPlan® have CE mark. 510(k) for SagiNova® was obtained
recently which enables Eckert&Ziegler BEBIG to expand into the U.S.
brachytherapy market with an estimated 2,400 radiation therapy centers. For
any further requests, please contact your local Eckert&Ziegler BEBIG
representative or visit us on ESTRO booth #1500 from April 24th to April
27th, 2015!

About Eckert&Ziegler BEBIG
Contributing to saving lives!
Eckert&Ziegler BEBIG is a global provider of radiotherapy products and a
brachytherapy leader in Europe. The company's offices and subsidiaries are
located in Belgium, Germany, France, Spain, UK, Italy, the USA, Brazil and
India. In addition, Eckert&Ziegler BEBIG has a worldwide network of
distributors and agents to support the international marketing and
distribution of its product line.
Eckert&Ziegler BEBIG is dynamically growing company and employs currently more
than 200 people all over the globe. With its' annual turnover of about 30
million Euro the company pursues a strategy of continuous market expansion
and permanent improvement of its product portfolio to support optimally the
fight against cancer.

Eckert&Ziegler BEBIG has been listed on the Euronext stock exchange since
April 1997.

Claudia Wolf
Head of Marketing
Tel: +49 30 94 10 84 272


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert&Ziegler BEBIG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.